Lantern Pharma Inc.

NasdaqCM:LTRN Stok Raporu

Piyasa değeri: US$24.0m

Lantern Pharma Yönetim

Yönetim kriter kontrolleri 4/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Panna Sharma

İcra Kurulu Başkanı

US$763.8k

Toplam tazminat

CEO maaş yüzdesi75.29%
CEO görev süresi7.8yrs
CEO sahipliğin/a
Yönetim ortalama görev süresi7.1yrs
Yönetim Kurulu ortalama görev süresi7.2yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • Nov 21

Here's Why Lantern Pharma (NASDAQ:LTRN) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analiz Makalesi • Feb 21

Will Lantern Pharma (NASDAQ:LTRN) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analiz Makalesi • Nov 05

Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analiz Makalesi • Jun 12

Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analiz Makalesi • Feb 28

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analiz Makalesi • Nov 06

We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analiz Makalesi • Jul 20

Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Apr 04

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analiz Makalesi • Dec 19

Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Sep 02

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 14

Lantern Pharma gets FDA nod to start mid-stage study of LP-300 in lung cancer

Lantern Pharma (NASDAQ:LTRN) said the U.S. Food and Drug Administration (FDA) cleared the company to proceed with a phase 2 trial of LP-300 for never smoker patients with advanced non-small cell lung cancer (NSCLC). The study, dubbed Harmonic, will include 90 patients of which about 2/3 patients will receive LP-300 in combination with chemotherapy, while 1/3rd will receive chemotherapy alone. The company expects enrollment to occur over the next 12 to 16 months across multiple sites in the U.S. The company noted that in a previous phase 3 study, a subset of never smoker patients with NSCLC receiving LP-300 with chemotherapy showed increased overall and two-year survival of 91% and 125%, respectively, compared to patients on chemotherapy alone. LTRN +2.88% to $6.08 premarket July 14
Analiz Makalesi • May 20

Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analiz Makalesi • Feb 02

Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analiz Makalesi • Oct 13

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 24

Lantern Pharma: Consider A Speculative Long-Term Investment In This AI Drug Discoverer

Lantern is This has proven to be an unpopular sector of biotech across the past 12 months, with a lack of tangible progress causing share prices of most companies to fall. Lantern has 2 clinical opportunities in never-smokers with NSCLC and Prostate cancer, and significant funds with which to fund trials and potentially in-license more assets. The company hopes to create a powerful drug development platform in RADR, its data store, but realistically a decade's more data may be required to generate meaningful insight. Near-term price catalysts seem to lack real promise, but you can never rule out a sudden breakthrough. Lantern could also interest investors with a long-term time frame looking for drug development exposure.
Analiz Makalesi • May 05

We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analiz Makalesi • Feb 19

Here's What Lantern Pharma Inc.'s (NASDAQ:LTRN) Shareholder Ownership Structure Looks Like

Every investor in Lantern Pharma Inc. ( NASDAQ:LTRN ) should be aware of the most powerful shareholder groups. Large...

CEO Tazminat Analizi

Panna Sharma'un ücretlendirmesi Lantern Pharma'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Dec 31 2025US$764kUS$575k

-US$17m

Sep 30 2025n/an/a

-US$19m

Jun 30 2025n/an/a

-US$19m

Mar 31 2025n/an/a

-US$20m

Dec 31 2024US$1mUS$575k

-US$21m

Sep 30 2024n/an/a

-US$19m

Jun 30 2024n/an/a

-US$18m

Mar 31 2024n/an/a

-US$18m

Dec 31 2023US$684kUS$525k

-US$16m

Sep 30 2023n/an/a

-US$15m

Jun 30 2023n/an/a

-US$14m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$1mUS$475k

-US$14m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$16m

Mar 31 2022n/an/a

-US$14m

Dec 31 2021US$622kUS$432k

-US$12m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$9m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$2mUS$384k

-US$6m

Sep 30 2020n/an/a

-US$4m

Jun 30 2020n/an/a

-US$3m

Mar 31 2020n/an/a

-US$2m

Dec 31 2019US$332kUS$267k

-US$2m

Tazminat ve Piyasa: Panna 'ın toplam tazminatı ($USD 763.75K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 622.00K ).

Tazminat ve Kazançlar: Panna 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Panna Sharma (54 yo)

7.8yrs
Görev süresi
US$763,750
Tazminat

Mr. Panna L. Sharma, served as the Chief Executive Officer and President of Cancer Genetics, Inc. from May 2010 to February 02, 2018. Mr. Sharma founded TSG Partners (also known as The Sharma Group) in 200...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Panna Sharma
President7.8yrsUS$763.75kVeri yok
David Margrave
CFO & Secretary7.9yrsUS$585.58k0%
$ 0
Kishor Bhatia
Chief Scientific Officer & Scientific Consultant6.4yrsUS$244.42k0%
$ 0
Peter Nara
Co-Founder & Advisorno dataUS$794.00Veri yok
Marc Chamberlain
Chief Medical Officer of Starlight Therapeutics2.3yrsVeri yokVeri yok
7.1yrs
Ortalama Görev Süresi
64yo
Ortalama Yaş

Deneyimli Yönetim: LTRN 'un yönetim ekibi deneyimli ve deneyimlidir ( 7.1 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Panna Sharma
President7.8yrsUS$763.75kVeri yok
Vijay Chandru
Independent Director6.6yrsUS$51.00k0%
$ 0
Maria Maccecchini
Independent Director3.9yrsUS$51.00k0%
$ 0
Donald Keyser
Independent Chairman8.3yrsUS$56.00k0.41%
$ 97.9k
Lee Schalop
Independent Directorless than a yearUS$36.23kVeri yok
David Silberstein
Independent Director7.9yrsUS$46.00k0%
$ 0
7.2yrs
Ortalama Görev Süresi
71.5yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: LTRN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.2 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/07 08:46
Gün Sonu Hisse Fiyatı2026/05/07 00:00
Kazançlar2025/12/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Lantern Pharma Inc. 2 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Chad MesserLake Street Capital Markets, LLC
Ashok KumarThinkEquity LLC